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One sentence summary: Low intrinsic efficacy can explain the reduced side effects of apparently biased -
opioid receptor agonists. 
 
 
Editor's Summary: 
The antinociceptive effects of the -opioid receptor (MOR) have made this receptor a powerful target for pain 
management, but serious side effects limit their use. Because the MOR is a G protein–coupled receptor (GPCR) 
that stimulates intracellular signaling through both G proteins and -arrestins, biased agonists that primarily 
stimulate G protein signaling have been developed to promote pain relief without stimulating unwanted side 
effects. Gillis et al. compared the biochemical, signaling, and physiological properties of some of these G 
protein–biased MOR agonists with those of opioids that do not exhibit biased signaling. The  authors found that 
the observed reductions in side effects could be explained by the low intrinsic efficacy of the biased agonists 
rather than their signaling bias per se. These findings suggest strategies for developing new agonists that relieve 
pain with fewer unwanted side effects. 
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Abstract  
 
Biased agonism at G protein–coupled receptors (GPCRs) describes the phenomenon whereby some drugs can 
activate some downstream signaling activities to the relative exclusion of others. Descriptions of biased agonism 
focusing on the differential engagement of G proteins versus -arrestins are commonly limited by the small 
response windows obtained in pathways that are not amplified or are less effectively coupled to receptor 
engagement, such as -arrestin recruitment. At the -opioid receptor (MOR), G protein–biased ligands have 
been proposed to induce less constipationory and respiratory depressant side effects than opioids commonly 
used to treat pain. However, it is unclear whether these improved safety profiles are due to a reduction in -
arrestin–mediated signaling or, alternatively, to their low intrinsic efficacy in all signaling pathways. Here, we 
systematically evaluated the most recent and promising MOR biased ligands and assessed their pharmacological 
profile against existing opioid analgesics in assays not confounded by limited signal windows. We found that 
oliceridine, PZM21, and SR-17018 had low intrinsic efficacy. We also demonstrated a strong correlation 
between measures of efficacy for receptor activation, G protein coupling and -arrestin recruitment for all tested 
ligands. By measuring the anti-nociceptiveantinociceptive and respiratory depressant effects of these ligands, we 
showed that low intrinsic efficacy of opioid ligands can explain an improved side effect profile. Our results 
establish a possible alternative mechanism underlying the improved therapeutic windows described for new 
opioid ligands, which should be taken into account for future descriptions of ligand action at this important 
therapeutic target. 
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Introduction 
 
Agonists of the µ-opioid receptor (MOR), such as morphine and the synthetic opioid fentanyl, are mainstay 
analgesics for the treatment for severe acute pain. Unfortunately, MOR agonists also elicit several on-target 
adverse effects that severely limit their use, including respiratory depression, constipation, and the development 
of tolerance and addiction. The MOR is predominantly coupled to the Gi/o protein family, which signals by 
inhibiting the production of cyclic AMP (cAMP) by adenylyl cyclase (AC) via G-subunits, and activating G 
protein–coupled inwardly rectifying potassium (GIRK) channels through G subunits, among other effectors 
(1) [1]. Similar to most other G protein–coupled receptors (GPCRs), MOR signalling is regulated by the 
phosphorylation of intracellular C-terminal serine and threonine residues, which stabilizes the binding of -
arrestins. This family of cytosolic scaffolding proteins are understood to terminate G protein signalling and 
mediate the formation of endocytic complexes and receptor internalization. 
 
-arrestin 2 has attracted much interest in regard to its interactions with MOR due to its suggested involvement 
in opioid side effects. Early studies showed enhanced morphine analgesia in -arrestin 2 knockout mice with 
greatly diminished respiratory depression and constipation (2, 3). This has led to the hypothesis that a putative 
arrestin-dependent mechanism downstream of the MOR mediates the unwanted side effects of opioids (4). 
However, the nature of this proposed signal altering respiratory and gastrointestinal function has not been 
demonstrated. This ‘arrestin hypothesis’ has been challenged by the persistence of morphine- and fentanyl-
induced side effects, including respiratory depression and constipation, in a knock-in mouse expressing a 
phospho-deficient MOR mutant that is unable to recruit -arrestin (5) as well as by the persistence of morphine-
induced respiratory depression in the a -arrestin 2 knockout mouse (6)[6] (Kliewer et al. Br J Pharmacol In 
press) . Additionally, there is robust physiological evidence demonstrating that classical G protein signaling 
from the MOR contributes substantially to respiratory depression (7, 8), as well as to other side effects, such as 
constipation (9, 10).  
 
The proposed role of -arrestins in the unwanted effects of MOR agonists has led to the development of MOR 
ligands that do not recruit -arrestin 2 to the receptor, under the assumption that this would avoid on-target side 
effects mediated by the proposed -arrestin–dependent mechanism. Biased or functionally selective agonists 
engage a subset of signaling pathways to the exclusion of others , as in the case of G protein–biased ligands that 
maintain the classical G protein signal while reducing interactions with -arrestin 2. The prototypical such 
ligand of the MOR is oliceridine (TRV130), initially reported to have an improved pre-clinical profile over 
morphine in rodent studies (11) and now in clinical trials. Further studies have reinforced that oliceridine 
induces constipation and abuse-related effects in rodents (12, 13), and although it still induces respiratory 
depression and constipation in humans, these side effects may be reduced when compared to morphine, giving a 
potentially wider therapeutic window (14, 15). Another MOR ligand proposed to be G protein–biased, PZM21, 
was discovered using in silico docking to the inactive MOR crystal structure (16). Studies in cell lines as well as 
in neurons of MOR-Venus knock-in mice have further shown that both oliceridine and PZM21 induce very 
limited -arrestin recruitment or receptor internalization (17). The authors suggested that oliceridine and PZM21 
have a signaling signature similar to buprenorphine, an extremely low-efficacy MOR agonist with reduced risk 
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of severe adverse effects. Although initially reported not to induce respiratory depression  (16)[14], a later study 
found that PZM21 did slow respiratory frequency in mice to a similar extent as did morphine (18). Schmid et al. 
(19) generated a series of MOR ligands with increasing degrees of separation between G protein coupling, as 
measured by GTPS binding and inhibition of cAMP accumulation, and -arrestin coupling, and correlated the 
quantitative bias factors to the therapeutic window of these compounds. Of these ligands, SR-17018 was the 
compound with the most extreme apparent bias and the best separation between anti-nociception and respiratory 
side effects, because it was reported to not alter blood oxygen saturation or respiratory frequency in mice (19). 
 
New MOR agonists proposed to be G protein–biased appear to have other pharmacological properties that could 
potentially be related to their safety profiles (20), and the mechanism through which reduced recruitment of  -
arrestin 2 to the MOR could reduce side effects remains unclear. Characterization of biased agonists is 
complicated by the difficulty in accurately quantifying agonist activity for a given signaling pathway. The de 
facto standard for bias quantification is the operational model of agonism (21). This model, by design, 
mathematically accounts for the distinct pharmacological parameters of affinity (ligand binding to a target) and 
efficacy (ligand-induced activation of that target). Operational model analysis of bias is routinely performed by 
estimating a combined “transducer coefficient” as an index of intrinsic relative activity of an agonist for a given 
pathway. This can be normalized to a reference agonist to allow comparison of activity between pathways, 
through quantitative test agonist bias factors, presumably without system bias. However, there are important 
confounding factors that must be considered in the application of operational analysis  to any system. Ligand 
binding kinetics and the temporal pattern of signaling processes are not accounted for in this an alysis and can 
have a profound influence on apparent bias (22). Additionally, test compounds with very low activity for a 
particular end-point severely confound accurate quantification. Assays in which agonists produce no or minimal 
signal prevent satisfactory curve fit and, therefore, any robust estimation of bias using the operational model. 
 
Regardless of the model, identification of biased agonists requires estimation of agonist efficacy and affinity 
independent of system and observational bias, such as cellular background and assay conditions. Initial 
descriptions of proposed G protein–biased MOR agonists did not specifically quantify agonist efficacy, giving 
either combined transduction coefficients (16, 19) or not directly quantifying bias (11). Assays of G protein 
activity are commonly confounded by the presence of receptor reserve (also known as spare receptors), which is 
the condition whereby an agonist needs to activate only a small fraction of the existing receptor population to 
produce the maximal system response (23, 24)[21, 24]. In the presence of high receptor reserve, most test 
agonists reach a similar maximal response, preventing straightforward determination of relative efficacy (23). It 
is only when there is low receptor reserve that the differences in efficacy become apparent. In such cases, 
irreversible receptor inactivation removes receptor reserve and allows the quantification of ligand-intrinsic 
efficacy (23). Similarly, low-efficacy agonists, when compared between G protein assays, which measure highly 
amplified signalling, and -arrestin recruitment measurements, which measure unamplified signals, may appear 
biased due to assay conditions (20). As such, recent studies showing the low efficacy of putatively biased 
agonists (18, 25, 26) should prompt a re-examination of the signaling profile of these biased MOR agonists, 
given that this factor was not initially identified. 
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Similar to bias factors, accurate quantification of a pre-clinical ‘therapeutic window’ of lead compounds in vivo 
is critical to drug development. In this context, therapeutic window indicates the separation between the dose of 
a compound producing analgesic effect and the dose resulting in side effects such as respiratory depression or 
constipation. Therapeutic window is typically quantified pre-clinically by comparison of the potency of a 
compound for each response. The activity of test agonists in animal assays of anti-nociception and side effects is 
highly context-dependent. As such, measures of agonist bias and safety profiles using different in vitro assays, 
varying in vivo models, and inconsistent mathematical analyses does not allow for direct comparison of biased 
MOR agonists described in separate studies. 
 
Here, we provide a systematic evaluation of the most recent and promising MOR biased ligands and assess their 
pharmacological profiles against existing opioid analgesics in assays that are not confounded by limited signal 
windows. We found that oliceridine, PZM21, and SR-17018 have very low intrinsic efficacy. We also 
demonstrated a strong correlation between measures of efficacy for receptor activation, G protein coupling, and 
-arrestin recruitment for all tested ligands, including those that have previously been described as biased. 
Finally, by measuring the antinociceptive and respiratory depressant effects of these ligands, we showed that 
low intrinsic efficacy of the so-called biased ligands can explain their improved side effect profiles in terms of a 
continuum of existing analgesics. Our results therefore suggest an alternative mechanism underlying the 
improved therapeutic windows described for novel opioid ligands, which should be taken into account for future 
descriptions of ligand action at this important therapeutic target. 
 
 
Results 
 
In vitro responses of different opioid ligands reveal a spectrum of maximal effects 
 
To understand the relationship between the intrinsic efficacy of opioids for different signalling pathways and, 
eventually, to assess their correlation with therapeutic indices, we constructed concentration -response curves for 
several opioid ligands and multiple downstream signaling pathways proximally linked to MOR activation in 
HEK293 cells (Fig. 1A).  An analogue of the endogenous opioid peptide Met-enkephalin, DAMGO, was used 
as a reference agonist (16, 19, 24, 27). Existing clinical opioid agonists fentanyl, methadone, morphine, 
oxycodone and buprenorphine were profiled along with the three most recently described G protein–biased 
agonists oliceridine, PZM21, and SR-17018 (11, 16, 19).  The ability of ligands to induce the active 
conformation of MOR was monitored through bioluminescence resonance energy transfer (BRET) assays for 
the recruitment of a conformationally selective nanobody (Nanobody 33-Venus, Nb33-Venus) to the receptor 
(Fig. 1B) (28). Similarly, coupling to and activation of Gi-proteins was assessed using, respectively, BRET 
assays with truncated, soluble ‘mini’ Gi-proteins fused to a Venus fluorescent protein (mGsi-Venus, Fig. 1C) 
(29) or previously described Gi2 activation BRET-based biosensors (Fig. 1D) (30, 31). Subsequent Gi-
mediated inhibition of forskolin-induced cAMP production was monitored using the cAMP-YFP-Epac-RLuc 
(CAMYEL) BRET-based sensor (Fig. 1E) (32). G-mediated activation of GIRK channels in response to 
MOR ligands was measured using a membrane potential–sensitive dye assay in the absence or presence of the 
irreversible antagonist -chlornaltrexamine (-CNA) to reduce receptor reserve (Fig. 1F, fig. S1A).  
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We also constructed concentration-response curves of the nine opioid ligands using BRET assays to monitor 
GRK2 and -arrestin 2 recruitment (Fig. 2, A–C), as well as MOR trafficking to Rab5a-positive endocytic 
compartments (Fig. 2D). Of note, to improve assay signal, we overexpressed GRK2 in the -arrestin 2 
recruitment and MOR trafficking assays (33), because we could not obtain a quantifiable response to all ligands 
with only endogenous amounts of GRK in these assays (fig. S1B, S1C). Altogether, we constructed 
concentration-response curves to accurately measure the responses the nine ligands of interest. These curves 
were then used to estimate signalling efficacy and biased factors.  
 
Oliceridine, PZM21, and SR-17018 have low intrinsic efficacy for receptor activation and G protein 
signalling 
 
Signaling efficacy was estimated using the operational model of agonism and quantified as the operational 
efficacy, , a parameter comprised of both receptor density and signaling efficiency of the agonist -occupied 
receptor (Table 3, see Materials and Methods for detailed description of the analyses). In all G protein assays 
oliceridine, PZM21, and SR-17018 had lower intrinsic efficacy than did morphine, itself a partial agonist 
relative to fentanyl and DAMGO (Fig. 2E). Oxycodone had similar efficacy to morphine, and buprenorphine 
had very low efficacy. Together, these assays capture different aspects of receptor–G protein coupling and the 
amounts of signal amplification. In pathways with very limited  signal amplification due to direct proximity to 
receptor activation (Nb33 recruitment, mGsi recruitment) or with very limited receptor reserve from partial 
irreversible antagonism (GIRK activation) partial agonists had  lower efficacy and potency than in highly 
amplified pathways (Gi2 activation and AC inhibition) (Tables 1 and 2). In pathways proximal to receptor 
activation (Nb33 recruitment, mGsi recruitment) or with very limited receptor reserve (GIRK activation) partial 
agonists had  lower efficacy and potency than in highly amplified, strongly coupled pathways (Gi2 activation 
and AC inhibition) (Tables 1 and 2). However, despite these differences, estimates of relative efficacy for 
activating G proteins were remarkably consistent across assays of receptor and G protein activation. In addition, 
assays of receptor regulation, including interactions between MOR and GRK2, -arrestin 2, and Rab5, showed a 
similar pattern of agonist efficacy with rank order of maximal effect largely conserved across all assays. 
Oliceridine, PZM21, SR-17018, and buprenorphine displayed lower efficacy in receptor regulation than did 
oxycodone and morphine (Fig. 2E and Table 1).  
 
We also monitored the kinetics of receptor-effector coupling in real-time assays of Nb33 and mGsi recruitment. 
SR-17018 recruited Nb33 and mGsi to the MOR at a slower rate than did morphine, DAMGO or the other 
putatively biased compounds oliceridine and PZM21 (fig. S2, A and B). The maximum response to SR-17018 
did not occur until 5 minutes after agonist addition, whereas it occurred within 1 minute of stimulation with 
oliceridine, PZM21, or buprenorphine. Recruitment of Nb33 and mGsi to the MOR by oliceridine, PZM21, and 
SR-17018 was rapidly reversed following addition of 10 µM the MOR antagonist naloxone, but that induced by 
buprenorphine was not. This was due to either the inability of naloxone to compete with the very high affinity of 
buprenorphine or to the extremely slow dissociation rate of this compound, or some combination of the two. 
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Agonist-induced C-terminal phosphorylation of MOR, quantified by phosphosite-specific antibodies, was in 
agreement with the different efficacy profiles.  DAMGO, fentanyl, and methadone induced multi-site 
phosphorylation of MOR, as expected for high-efficacy opioids (34), whereas morphine, oxycodone, 
oliceridine, and PZM21 only triggered phosphorylation of Ser375 (Fig. 3A) (34, 35). We have previously shown 
buprenorphine to have a phosphorylation profile restricted to Ser375, typical of low-efficacy agonists (34). The 
phosphorylation profile of SR-17018 was unusual in that even though concentrations up to 10 M did not 
produce substantial phosphorylation of residues other than Ser375 up until 30 min of stimulation (Fig. 3B), the 
MOR phosphorylation pattern induced by SR-17018 resembled that of higher efficacy ligands at the longest 
incubation time point (Fig. 3A). Moreover, similar to high-efficacy agonists, this multi-site phosphorylation 
depended on GRK2 or GRK3 (GRK2/3), because it was blocked by incubation with the GRK2/3 inhibitor 
Cmpd101 (fig. S3B). Naloxone blocked the phosphorylation of MOR induced by SR-17018, oliceridine, or 
PZM21 (fig. S3A). Such unusual behavior for SR-17018 may also be linked to -arrestin recruitment data 
obtained using a high temporal resolution Förster resonance-energy transfer (FRET) approach, wherein SR-
17018 responses showed delayed onset of arrestin recruitment (similar to Nb33 and mG si from fig. S2) and very 
slow decay upon agonist washout relative to other agonists,  although this observation was difficult to 
consistently reproduce and warrants further investigation (fig. S4). 
 
Efficacy for G protein pathways closely predicts efficacy in receptor regulatory pathways  
To investigate the relationship between efficacy values of the test agonists in different pathways, we calculated 
correlation coefficients (Pearson’s r) between log() values (Fig. 4, fig. S5, A and B). There was robust 
correlation between the efficacy of test partial agonists in all pathways linked to G protein activation. The log() 
obtained for Gi2 activation significantly correlated with the log() estimated for receptor activation by Nb33 
recruitment (Fig. 4A), mGsi recruitment (Fig. 4B), cAMP inhibition (Fig. 4C), and GIRK activation (Fig. 4D, 
coefficient of determination ≥ 0.79 in all cases). Similarly, estimated efficacy of test compounds was consistent 
in receptor regulatory pathways. The log() value of the agonists for -arrestin2 recruitment correlated very 
tightly to that calculated for receptor activation (Nb33) (Fig. 4E), GRK2 recruitment (Fig. 4F), and Rab5-
positive endosome trafficking (Fig. 4G). Surprisingly, efficacy for G protein pathways closely predicted efficacy 
in receptor regulatory pathways for all agonists, even those proposed to be biased. The log() for -arrestin 
recruitment significantly correlated with the log() of G protein coupling (mGsi recruitment) (Fig. 4H) and with 
the activation of both Gi2 (Fig. 4I) and GIRK channels (Fig. 4J, coefficient of determination ≥ 0.80). A less 
robust correlation was observed between the efficacy for -arrestin recruitment and cAMP inhibition, which is 
likely due to the high amplification and receptor reserve of the cAMP assay that results in poorer relative 
efficacy estimates (Fig. 4K). Together, these results show that oliceridine, PZM21, and SR-17018 exhibited 
consistently low intrinsic efficacy regardless of the downstream signaling pathway that was monitored, similar 
to that observed for buprenorphine and lower than that for morphine and oxycodone. Fentanyl and methadone 
were high-efficacy agonists, similar to DAMGO, in all assays in which they were studied.  For each of the 
family of compounds tested and across a battery of G protein and regulatory assays, relative efficacy was highly 
conserved. 
 
The close correlation of efficacy across assays suggested that test agonists had similar activity in both G protein 
and regulatory pathways. In order to test this with a common, standard measure, we used the operational model 
of agonism to calculate the bias factors of all the ligands across the different signaling pathways that were 
assayed (see Materials and Methods). No evidence of significant bias was observed towards G protein signaling 
compared to -arrestin 2 recruitment even after overexpression of GRK2 to ensure detectable and quantifiable 
responses from all ligands. The only exception was fentanyl showing a slight preference for GIRK activation 
(Fig. 5, fig S6A, Table S1). Unexpectedly, SR-17018, which was initially described as a ligand with an 
extremely high G protein bias, showed no significant bias toward or away from any G protein activation 
measure, with a direction of bias toward Nb33 recruitment over -arrestin 2 recruitment but low confidence in 
that estimate. Buprenorphine showed a significant bias away from GIRK activation toward -arrestin 2 
recruitment. 
 
These bias profiles were different when measured with only endogenous GRK expression (fig. S6B). Although 
not statistically significant, oliceridine, PZM21, and buprenorphine showed bias factors in the direction of Nb33 
and mGsi recruitment and Gαi2 and GIRK activation over -arrestin 2 recruitment in these conditions. However, 
poor curve fits for these extremely partial agonists in the -arrestin 2 recruitment assay without kinase 
overexpression reduced the confidence in estimates of transduction coefficient and bias (fig. S6A). 
 
The low intrinsic efficacy of oliceridine, PZM21, SR-17018, and buprenorphine correlates with improved 
therapeutic windows 
 
Biased agonism has been postulated to underlie the improved therapeutic indices of several opioid ligands. We 
measured the abilities of fentanyl, morphine, oliceridine, PZM21, SR-17018, and buprenorphine to produce 
anti-nociception and respiratory depression in mice. The anti-nociceptiveantinociceptive action of these 
compounds has been shown to be abolished in MOR-knockout animals (16, 19, 36, 37) or to be sensitive to the 
MOR antagonist naloxone (11). These compounds represent the full range of opioid agonist efficacy we 
quantified in vitro. Compounds were tested at increasing doses in a hot-plate assay (anti-nociception) and 
whole-body plethysmography (respiratory depression) for 180 and 240 min, respectively. Compounds were 
delivered sub-cutaneously, with the exception of SR-17018, which was given by intra-peritoneal injection, as in 
previous studies (19), due to the viscous vehicle and larger volume required. 
 
The tested compounds produced robust anti-nociception (Fig. 6A), with the exception of SR-17018, which was 
dose-limited by solubility. The kinetics of the anti-nociceptiveantinociceptive effects were consistent with 
previously reported pharmacodynamics. Fentanyl and oliceridine had rapid onset of effect, followed by fast 
decay, aligning with their clinical profiles and animal studies (11). The onset and lifetime of the effect of 
morphine was intermediate, and although buprenorphine had similar onset to morphine, its effects on 
nociception were substantially longer-lasting, in line with previous research in pre-clinical and clinical settings 
(38). PZM21 and SR-17018 had long-lasting anti-nociceptiveantinociceptive effects, as previously reported (16, 
18, 19). 
 
The primary effect of opioid agonists on mouse respiratory function is a decrease in respiratory frequency. All 
tested agonists reduced respiratory frequency within the test period, albeit to varying extents (Fig. 6B). Minute 
volume, a combined measure of breath frequency and depth, was additionally measured over the test period and 
showed a very similar pattern between agonists (fig. S7). With the exception of buprenorphine, test compounds 
had very similar kinetics of effect between anti-nociception and respiratory depression. Buprenorphine did not 
have a significant effect on respiratory frequency until 230 minutes after injection at both 1 and 10 mg/kg, 
whereas all active anti-nociceptiveantinociceptive doses reached peak effect within 30 minutes. A more highly 
efficacious active metabolite of buprenorphine, norbuprenorphine, has previously been reported to contribute to 
respiratory depression following buprenorphine injection in mice (39, 40) and may explain this result. As 
previously published by Hill et al. (18) and in contradiction of the initial report of Manglik et al. (16), PZM21 
induced substantial respiratory depression at anti-nociceptiveantinociceptive doses. In contrast to the study of 
Schmid et al. (19), which measured respiratory depression in restrained animals, SR-17018 induced significant 
respiratory depression at the highest dose tested, 30 mg/kg, although this effect was  minimal compared to other 
agonists. The initial characterisation of SR-17018 employed restrained pulse oximetry in order to estimate 
respiratory frequency and tested until 60 minutes post-injection. The significant effects of SR-17018 on 
respiratory frequency were observed in our assay, in which animals were moving freely rather than being 
restrained, from 60 minutes onwards. As such, variations in the assay format or time-course may explain the 
differences in the observed effects. In addition, similar to the critical difference between the reports of Hill et al. 
(18) and Manglik et al. (16), the respiratory frequency of the vehicle-treated group in Schmid et al. (19) dropped 
substantially over the test period with approximately a 25% change in frequency, whereas the vehicle groups in 
the present study were more stable, changing by 15%. Comparison of the respiratory effects of different ligands 
at equally anti-nociceptiveantinociceptive doses revealed differences in the agonists’ relative potency for the 
two assays. Buprenorphine, oliceridine, PZM21, and SR-17018 produced less respiratory depression than did 
morphine or fentanyl at equi-antinociceptive doses (Fig. 6C). 
 
The peak effect of each dose from the hot plate and whole-body plethysmography data were then plotted in a 
dose-response curve (Fig. 7A). This allowed calculation of the potency, logED50, for each drug in each 
behavioral assay (Fig. 7B). Peak effect was used to allow the comparison between drugs with distinct kinetic 
profiles. A pre-clinical model of therapeutic window was calculated by subtraction of logED50 of 
antinociception from respiratory depression, with error propagated. Of note, because a curve fit was not possible 
for SR-17018 due to solubility-limited doses, potency for antinociception was taken as minimum dose reaching 
a peak effect of 50% MPE. In the case of respiratory frequency depression induced by buprenorphine and SR-
17018, neither of which reached 50% of the maximum effect of fentanyl, the highest tested dose was 
represented as a minimum lower bound of potency. Thus, the therapeutic windows of SR-17018 and 
buprenorphine were estimated and are shown as lower bounds (Fig. 8, A and B). Regardless, our results show 
that oliceridine has a larger therapeutic window in this pre-clinical model than morphine or fentanyl, with 
buprenorphine having the safest profile. PZM21 also appeared to have an improved therapeutic index but was 
less accurately quantified, whereas the window of SR-17018 was estimated. 
 
Finally, our systematic pharmacological characterization in HEK293 cells allowed us to investigate the 
relationship between in vivo therapeutic window and in vitro efficacy or bias factors. We observed an inverse 
relationship between efficacy and therapeutic window; high-efficacy compounds, such as fentanyl, had a very 
narrow safety index, whereas the lowest efficacy agonist, buprenorphine, had a broad therapeutic range (Fig. 
8A). Morphine, a drug less efficacious than fentanyl but more efficacious than buprenorphine, showed an 
intermediate safety profile. This characterization is broadly in line with clinical experience (41) and is supported 
by a comparison of the signaling profiles and FDA-reported adverse event frequencies of medically used 
opioids, which found an association between reduced efficacy and lower rates of adverse respiratory events 
(42). Importantly, all the so-called biased ligands (oliceridine, PZM21, and SR-17018) fell within this 
correlation, with efficacy and therapeutic windows falling in the range between morphine and buprenorphine. In 
contrast, bias factors calculated between any G protein pathway and -arrestin 2 recruitment did not predict 
therapeutic window (Fig. 8B, fig. S8B). As noted above, the efficacy of each compound was consistent between 
tested assays, such that efficacy in most pathways predicted therapeutic window (fig. S8A). Comparison of 
agonist activity with bias plots clearly shows that all tested compounds have similar relative activity between G 
protein and arrestin recruitment assays (Fig. 9, fig. S9). 
 
Discussion 
 
Biased agonism at the MOR has been the focus of intense research for over a decade. Early observations in -
arrestin 2 knockout mice prompted the hypothesis that this scaffolding protein participated in the signaling 
mechanisms mediating the on-target side-effects of morphine (2, 3). This gave rise to the second hypothesis that 
ligands able to activate G proteins without -arrestin recruitment represented a safer strategy to provide 
analgesia (43, 44). Oliceridine, PZM21, and SR-17018 represent the most prominent examples of opioid ligands 
with G protein bias, although only oliceridine has been clinically tested. However, this underlying hypothesis 
has recently been challenged. First, respiratory depression induced through the MOR has been shown to be at 
least partially mediated by receptor coupling to GIRK channels through the activation of G-proteins (7), with 
neurons in several regions of the brainstem respiratory network hyperpolarised by activation of this classical, -
arrestin–independent MOR signalling pathway (8). This contrasts to the absence of robust physiological 
evidence for a -arrestin signal from the MOR affecting respiratory function (45). Second, opioid side-effect 
profile is not improved in a knock-in mouse expressing a phosphorylation-deficient, G protein–biased MOR (5). 
Third, several laboratories have been unable to repeat the primary result of reduced morphine respiratory 
depression in the -arrestin 2 knockout(6) [6]. In this study, the systematic pharmacological characterization of 
these compounds in cell lines as well as in vivo allowed their direct comparison and evaluation against a panel 
of existing analgesics.  
 
We Here we found that efficacy robustly correlated across five assays of G protein signaling and across multiple 
assays of receptor regulation. The rank order of efficacy described here in heterologous expression signaling 
assays is consistent with other cellular and ex vivo studies performed with these ligands, including AtT20 cells 
and locus coeruleus (LC) neurons (46, 47) . The efficacy of all test agonists, including both existing analgesics 
and new compounds described as biased for -arrestin 2 recruitment, was closely predicted by accurate G 
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protein efficacy estimates. This suggests that MOR activation by these agonists is similar for all tested assays, 
and indeed operational analysis found no evidence of significant agonist bias . All three putatively biased 
agonists had consistently low efficacy compared to morphine. Although previous descriptions of biased MOR 
agonists by Manglik et al. (16) and Schmid et al. (19) did not quantify efficacy explicitly, it is possible to 
reanalyse the cell-based assays used in these studies, which show low receptor reserve and use DAMGO as a 
full reference agonist to generate efficacy estimates (Table 4S2,(23)). The efficacy of oliceridine, PZM21, and 
SR-17018 compared to morphine estimated in this manner aligns with our own characterization of these ligands 
as low-efficacy agonists, as well as with other studies (18, 25, 26). Work at the 2 adrenergic receptor (2AR) 
has suggested that different active-state receptor conformations are responsible for the lower efficacy of partial 
agonists [46, 47]. At the MOR, a recent report also suggests differential ligand-receptor interactions between 
differently biased agonists with similar intrinsic efficacy (endopmorphin-2 and bilorphin)[44], although these 
interactions have not yet been tested experimentally. However, the impact of such conformations to intracellular 
signalling as well as to in vivo GPCR-mediated responses still remains unknown. 
 
The relative potencies obtained from our concentration-response curves are also in agreement with previous 
reports (Table 2)(11, 16, 19, 24, 48). This is relevant because we designed each assay to quantitatively 
differentiate between responses to all test ligands, including very weak partial agonists such as buprenorphine. 
In assays with minimal amplification (specifically recruitment of Nb33, mGsi, GRK2, and -arrestin 2), which 
may be assumed to detect a direct, one-to-one interaction between receptor and the recruited protein, Emax of an 
agonist directly reflects efficacy (23). Indeed, this is the case upon comparison of agonist Emax values across 
these low-amplification assays. The maximal effect of each agonist was consistent between assays of 
recruitment (Table 1), as would be expected if it were assumed that these assays detect a direct, one-to-one 
interaction between receptor and recruited protein. In this circumstanceThus, with a lack of amplification, Emax 
values reflects efficacy directly and comparison across assays shows no evidence of agonist bias. 
 
The use of analytical methods such as those based on the Black and Leff operational model of agonism have 
provided a useful means to quantify agonist activity. The most accepted method for detection and quantification 
of biased agonism is comparison of “transduction coefficients” based on the Black and Leff operational model 
of agonism (49). However, these existing analytical methods are not robust for assays with substantial 
confounding factors. The kinetics of ligand binding and signal transduction (22), receptor and effector 
localization (50), as well as limited assay range in systems with high amplification or extremely partial agonists, 
may can all substantially alter conclusions regarding agonist activity. Using experimental approaches that allow 
for the measurement of responses in real time we captured the peak effect of each drug for each signal 
transduction pathway. This also allowed us to minimise minimize the influence of receptor desensitisation, 
which occurs rapidly following stimulation, on measures of G protein activation (35). Moreover, our 
experimental setupOur approach also ensured that the assays used were not limited by narrow signal windows. 
This was achieved by using irreversible receptor inactivation for GIRK channel activation and exploiting the 
linear receptor-effector relationship with an excess of reporter in the case of both Nb33 and mGsi recruitment 
assays. In doing so, we captured the true range of MOR agonist efficacy. Similarly, we adjusted our 
experimental conditions to minimize the “floor” effect of ligands with minimal agonist activity  . This was the 
Commented [MC23]: We have deleted the following 
discussion as we don’t think it fits here. However this was a 
request of one reviewer and may need to be re-inserted. 
Commented [MC24]: In our opinion, this could be deleted. 
This was requested by a reviewer, but we don’t really feel it 
fits in the flow of the discussion.  
case in -arrestin 2 recruitment and internalization assays, wherein weby overexpressed overexpression of 
GRK2 to ensure a detection window that fitted all ligands (33). These considerations have a profound impact on 
the accuracy of bias quantification. 
 
When GRK2 was overexpressed, we did not observe bias for any of the compounds previously characterised 
characterized as G protein–biased (Fig. 5). Similarly, when examined under endogenous GRK expression, 
oliceridine, PZM21, and buprenorphine showed no significant G protein bias although there was a tendency in 
the direction of mGsi recruitment, Gi activation, and inhibition of cAMP accumulation (fig. S6B). Moreover, 
and as expected from the correlations between the efficacies of the ligands across different pathways (Fig.4), no 
significant bias was detected when using an alternative, efficacy-driven approach for bias determination (25) 
(fig. S6C). Quantification of ligands that display the pronounced partial agonism of these compounds in any 
low-amplification pathway is confounded by poor curve fit to low responses (51). No significant bias of 
oliceridine and PZM21 was previously observed with operational analysis (16). For SR-17018, which was 
previously described to have an extremely high bias factor toward GTPS and AC inhibition over -arrestin 2 
recruitment, we did not detect bias toward any of the G protein pathways studied. The previous study compared 
activity in end-point assays between membranes of CHO cells (GTPS), whole CHO cells (cAMP 
accumulation), whole U2OS cells (-arrestin 2 recruitment), and membranes from mouse brain (GTPS). As 
described above, the current study used real-time assays on a consistent cellular background. Given the notably 
unique kinetics of SR-17018 across assays, capturing peak effect rather than a pre-defined end-point may 
partially explain discrepancies. Additionally, Schmid et al (2017) constrained the parameters of operational 
analysis to permit a curve-fit to extremely low activity compounds in the -arrestin 2 recruitment assay. As 
shown extensively by Stahl et al. (51), operational curve fitting to extremely low responses produces large 
variability in parameter estimates. 
 
GRK2 overexpression, matching the heterologous overexpression of MOR and -arrestin 2, improves assay 
signal-to-noise and therefore improved the statistical confidence. Poor quantification of curve position and 
plateau due to assay parameters is likely partly responsible for differences between our conclusions and those of 
some previous studies. As discussed theoretically by Conibear & Kelly (20), intrinsic system bias may give rise 
to substantial differences between assays and apparent agonist bias, particularly for low-efficacy agonists 
compared between highly amplified and linear signalling pathways. Low-efficacy agonists, such as 
buprenorphine and the putatively biased compounds, will produce strong responses in highly amplified G 
protein assays while having little activity in no-amplification, protein-protein interaction assays such as -
arrestin recruitment (52, 53). Indeed, buprenorphine itself has been previously proposed to be a G protein–
biased ligand (17, 54) though here and in previous studies it has consistently been observed to be an extremely 
partial agonist (24). This reinforces how varying signal amplification across assays can confound interpretation, 
most profoundly in the case of partial agonists. 
 
Given the issues highlighted with operational analysis, including criticism of its application to linear system s 
such as arrestin recruitment [21], graphical representation of agonist activity in ‘bias plots’ is an accepted 
accessory measure for the identification of biased agonists [49, 55]. Equimolar comparison of each agonist’s 
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activity in G protein activation and -arrestin 2 recruitment, both with and without GRK2 overexpression, 
illustrates the differences in signal amplification between these assays (Fig. 9, fig. S9) (49, 55). Qualitative 
comparison of tThe location of a test agonist over this plot compared to a reference agonist is used to identify 
biased ligands using this method. Importantly, given the proposal of agonist bias, rRegardless of kinase 
overexpression all tested agonists produce similar levels of -arrestin 2 recruitment at a given amount of G 
protein activation. Observation of tThe substantial difference in amplification between G protein activation and 
-arrestin 2 recruitment under endogenous GRK expression illustrates how the window for detection of G 
protein–biased agonism in these conditions is limited. Similar results were obtained when comparing receptor 
activation, mGsi recruitment, cAMP inhibition, and GIRK channel activation both with and without receptor 
knockdown (fig. S9). 
 
We studied the efficacy of test ligands in assays explicitly designed to capture the true range of opioid agonist 
signalling. These assaysOur selection of opioids recapitulated recapitulates the knowna large range of efficacy 
of existing opioid analgesics, from low-efficacy buprenorphine to high-efficacy fentanyl, in a wider range of 
functional responses (24). Buprenorphine is an opioid with unique pharmacology, having extremely high 
affinity with low partial agonism at MOR, antagonism of -opioid receptors (KORs), and interactions with the 
nociceptin/opioid-like receptor (ORL1) (56). It has been well characterized as having a ‘ceiling’ effect on 
respiration in both rodent and human studies, whereby increasing doses well past the therapeutic range do not 
additionally depress breathing (57). and It has been implicated in lethal overdose much less frequently than 
other opioids (58). Buprenorphine’s low intrinsic efficacy is routinely assumed to underly this plateau of effect 
on human respiration, and this partial agonism did not appear to limit the clinical analgesic effect in a review of 
clinical trials (59). Indeed, a review from a consensus group concluded that buprenorphine produced equivalent 
analgesia to full opioid agonists with reduced likelihood of severe respiratory depression (60). A confounding 
factor in the study of this agonist, in addition to its lack of selectivity, is the production of active metabolites 
such as norbuprenorphine, which has lower affinity but higher efficacy than the parent compound (61). As noted 
above, this metabolite has been implicated in pre-clinical studies of buprenorphine respiratory depression and, in 
the rare cases of mortality, has been detected in blood plasma in amounts similar to that of buprenorphine (62). 
The accumulation of active metabolites is a potential explanation for the delayed effect of buprenorphine on 
respiratory depression in the present study (Fig. 6B). In any case, given that buprenorphine’s anti-
nociceptiveantinociceptive effect in mice is abolished by MOR knockout (37), its superior profile here can be 
understood through its partial agonism at that receptor. Other opioids with very low intrinsic efficacy, including 
dezocine and nalbuphine, have also been shown to have ceiling effects on respiration in human studies (63, 64). 
A meta-analysis of randomised controlled trials concluded that nalbuphine produced equivalent analgesia to 
morphine (65). By contrast, the high-efficacy analgesic fentanyl has a very narrow window of therapeutic effect 
versus respiratory depression (66). 
 
In the this context of buprenorphine’s improved profile, both clinically and in pre-clinical models, relative to 
that of morphine and the high-efficacy agonist fentanyl, we have identified that the therapeutic window of 
putatively biased MOR agonists has a potential alternative mechanism. Although still inducing similar levels of 
respiratory depression to morphine at high doses, oliceridine had a slightly but significantly improved window 
that is in line with previous pre-clinical and clinical work (11, 67). Similarly, PZM21, though not as accurately 
quantified due to lower potency and solubility concerns, appeared to have an equivalent increase in window, as 
did the estimated profile of SR-17018. Given the challenges to the arrestin hypothesis detailed above, the low 
intrinsic efficacy of these compounds is a more plausible explanation for these results.  
 
Intrinsic efficacy, as estimated in any pathway, robustly predicted the rank order of the test compounds in an in 
vivo model of separation between anti-nociception and respiratory depression, arguably the most clinically 
important opioid-induced side effect (Fig, 8A, fig. S8A). It will be of interest in future to determine if other 
adverse effects, such as the severity of constipation, tolerance, and physical dependence exhibit comparable 
correlations. Buprenorphine’s therapeutic utility is limited by its poor bioavailability, active metabolites, and 
concerns around its extremely high MOR affinity, including reversibility of respiratory depression and complex 
pharmacodynamic and kinetic relationships. The new MOR ligands studied here may have advantages in these 
and other aspects that make them superior platforms for further drug development. The contribution of off-target 
effects, most critically interactions with KOR, -opioid receptor (DOR), and ORL1, to this pre-clinical model 
was not directly examined here. The test agonists all have higher potency for MOR signalling over other targets, 
and MOR knockout abolishes the anti-nociceptiveantinociceptive effects of fentanyl, morphine, buprenorphine, 
PZM21, and SR-17018 (16, 19, 37), whereas oliceridine’s effects are naloxone-sensitive (11). Administration of 
selective DOR and KOR agonists (DPDPE and U69,593 respectively), had no significant effect on respiration in 
a previous study on a panel of opioids in rats [68]. Our data from the pre-clinical therapeutic window model 
therefore most likely reflects primarily MOR-mediated effects of these agonists, although off-target effects 
could contribute to opioid effects, particularly at high doses. Additionally, distinct pharmacokinetics have been 
proposed to contribute to differences in opioid respiratory depression (66) although . Herehere we showed that, 
for most agonists, the kinetics of anti-nociception and effects on respiratory frequency were consistent, and that 
kinetically ‘fast’ agonists did not have a consistently poorer  or superior profile. 
 
The phosphorylation pattern, or “barcode”, of the carboxy tail of the MOR is also indicative of the ability of 
opioid ligands to promote -arrestin recruitment and receptor internalization. It is widely accepted that high-
efficacy ligands trigger robust hierarchical and sequential multisite receptor phosphorylati on, whereas low-
efficacy ligands only induce phosphorylation of Ser375 in mice (Ser377 in humans). Such differential 
phosphorylation has previously been described for DAMGO, fentanyl, oxycodone, morphine , and 
buprenorphine (34, 35). Our data show that the phosphorylation induced by oliceridine and PZM21, even at 10 
M for 30 min, is limited to Ser375, supporting their classification as low-efficacy ligands. Of note, although the 
phosphorylation of Ser375 by oliceridine had previously been reported (11), its potential phosphorylation barcode 
had not been previously assayed. The phosphorylation pattern induced by SR-17018 during the first 20 min of 
incubation agrees with that of a low-efficacy agonist. After additional incubation, up toHowever, after 30 min, 
the MOR phosphorylation induced by this ligand resembled that of the high-efficacy ligands, both in terms of 
the pattern as well as in terms of its sensitivity to GRK2 inhibitors. Thus, although the pharmacological 
characterisation characterization of SR-17018 in vitro and in vivo suggest that its actions could be explained by 
its low intrinsic activity, these latter observations suggest that an unappreciated mechanism of action of SR-
17018 may still contribute to in vivo effects. Unfortunately, due to solubility concerns at high doses, the 
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Taken together our results draw attention to alternative mechanisms that influence the in vivo safety profiles of 
opioid ligands with regards to analgesia and respiratory depression. Whereas biased agonism is one hypothesis 
that may rationalize opioid actions, pharmacological parameters such as low G protein efficacy may also 
plausibly underlie the favourable therapeutic window of new opioids and should be taken into account. Given 
that the existing extremely low–efficacy agonist, buprenorphine, has been shown to produce reasonable 
analgesia with reduced side effects and overdose liability, but is limited by a complex pharmacological profile, 
there is clear scope for future drug development to optimize efficacy at this target.  
 
  
Materials and Methods  
 
Drugs 
Oliceridine (TRV130) hydrochloride was supplied by Adooq Bioscience, CA, USA as distributed by Sapphire 
Bioscience, Australia. Morphine hydrochloride was supplied by GlaxoSmithKline, Australia  or by Hameln Inc., 
Hameln, Germany. Buprenorphine was supplied by the National Measurement Institute, Department of Industry, 
Innovation and Science, Australia. PZM21 was supplied by (MedKoo Bioscience). SR-17018 was supplied 
synthesised as previously described (19). Oxycodone hydrochloride was supplied by Mundipharma; 
levomethadone hydrochloride was supplied by Sanofi-Aventis, and fentanyl citrate was supplied by Rotexmedica. 
Cmpd101 was from HelloBio. All other reagents were from SigmaAldrich. 
 
For in vivo compatible vehicle solubility, buprenorphine, PZM21 and SR-17018 were converted to hydrochloride 
salt form (see below). MS and NMR analysis confirmed the structures of buprenorphine, PZM21 and SR-17018 
used in animal assays was as previously published. 
 
Plasmids 
Nb33 cDNA was obtained from Mark von Zastrow and Ashish Manglik (28) and was subcloned into a Clontech 
pVenus vector resulting in addition of the Venus tag at the C-terminus. NES-Venus-mGsi (29), Rab5-Venus 
(68), Venus155-239-Gβ1, Venus1-155-Gγ2, masGRKct-RLuc8 (30, 69) were obtained from Nevin Lambert 
(University of Georgia, USA). FLAG-MOR-NLuc was generated by cloning FLAG-MOR (35) into a NLuc-
vector from Promega. GRK2-Venus was from D. Jensen (Columbia University, New York), β-arrestin2–YFP 
were provided by M. Caron (Duke University, North Carolina), GRK2 WT was from M. Smit (Vrije 
Universiteit, Amsterdam). CAMYEL sensor was from ATCC. 
 
Cell culture 
Human embryonic kidney 293 (HEK293) cells were maintained in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 5% v/v FBS at 37°C in a humidified atmosphere of 95% air and 5% CO 2. 
Transient transfections for BRET experiments were performed using linear polyethylenemine (PEI) with a 
molecular weight of 25kDa (Polysciences) at a DNA:PEI ratio of 1:6 as previously described  (35). Cells were 
transfected in a 10 cm dish with 1 μg of donor (FLAG-mMOP-NLuc) and 4 μg of acceptor (Nb33-Venus, mGsi-
Venus, GRK2-Venus, β-arrestin2-YFP or Rab5a-Venus). For G protein activation assays, cells were transfected 
with 2 μg of Gαi2, 1 μg of Venus155-239-Gβ1, 1 μg of Venus1-155-Gγ2 and 1 μg of masGRK3ct-Rluc8. For 
cAMP inhibition assays, cells were transfected with the CAMYEL BRET biosensor (2.5 μg of FLAG -mMOP 
and 2.5 μg of CAMYEL biosensor per dish). For GRK2 overexpression experiments, cells were co -transfected 
with an additional 2 μg of GRK2 WT. 
 
The coding DNA sequence for human GIRK4 (NM_000890.3) with a single c-myc tag inserted between GIRK4 
amino acids 121V and 122G was synthesised by GenScript in pUC57. The GIRK4 construct was then subcloned 
into pcDNA3.1+ (ThermoFisher, MA, USA). HEK293 cells stably expressing GIRK4 channels (HEK293-
GIRK4) were generated by transfecting the GIRK4-pcDNA3.1+ plasmid into HEK-Flp-in-293 cells 
(ThermoFisher, R75007). FLAG-mMOR in pcDNA5/FRT was subsequently stably transfected into the vacant 
Flp-In site according to the manufacturer’s instructions (ThermoFisher). HEK293-GIRK4-mMOR cells were 
grown in DMEM (Gibco ThermoFisher) supplemented with 10% v/v fetal bovine serum and 
penicillin/streptomycin. 
 
Bioluminescence Resonance Energy Transfer (BRET) 
Cells were replated into poly-D-lysine–coated 96-well plates 24 h after transfection and allowed to adhere 
overnight. BRET experiments were performed 48 h post-transfection. Furimazine (Promega) was used for 
Nanoluciferase (NLuc)-tagged constructs and Coelenterazine h (NanoLight Technologies, AZ) was used for 
Renilla luciferase (RLuc8)-tagged constructs at a final concentration of 5 μM. Luciferase substrate was added 
immediately before dual fluorescence/luminescence measurement in a PHERAstar Omega plate reader (BMG 
LabTech). The BRET signal was calculated as the ratio of light emitted at 530 nm by YFP or Venus (optic 
module 535+/-30) over the light emitted at 430 nm by NLuc or Rluc8 (optic module 475+/-30). Concentration-
response curves were constructed from the 10 min time point after agonist addition for all pathways except 
Rab5-Venus for which concentration-response curves were constructed 30 min after stimulation. To measure 
agonist-induced adenylate cyclase (AC) inhibition, 10 μM forskolin was co-added with agonists to induce 
cAMP production. BRET signal from vehicle-treated cells was subtracted. 
 
Western blotting  
HEK293 cells stably expressing HA-MOR were seeded onto poly-L-lysine-coated 60 mm dishes and grown to 
90 % confluence. After cells were either exposed or not exposed to different agonist, cells were lysed in RIPA 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 % Nonidet P-40, 0,5 % sodium deoxycholate, 
0,1 % SDS) containing protease and phosphatase inhibitors (Complete mini and PhosSTOP; Roche 
Diagnostics). PierceTM HA epitope tag antibody agarose beads (Thermo Scientific) were used to enrich 
glycosylated proteins. To elute proteins from the beads the samples were incubated in SDS sample buffer for 25 
min at 43°C. Supernatants were separated from the beads, loaded on 8% SDS polyacrylamide gels and 
immunoblotted onto nitrocellulose afterwards. After blocking, membranes were incubated with either anti -
pT370, anti-pS375, anti-pT376 or anti-pT379 antibody, followed by detection using a chemiluminescence 
detection system. Blots were subsequently stripped and incubated again with the phosphorylation -independent 
antibody anti-HA to confirm equal loading of the gels. Protein bands on western blots were exposed to X-ray 
film. Films exposed in the linear range were then densitized using ImageJ 1.37v.  
 
Data analysis 
GraphPad Prism software (v. 8.0) was used for data and statistical analyses which are specifically described in 
the figure legends. Concentration–response curves were fitted assuming a Hill slope of unity using the following 
three parameter equation 
 
Response = Bottom +  
Top − Bottom
1 +  10(logEC50 −log[A])
 
Where Top and Bottom represent the maximal and minimal asymptote of the concentration-response curve, [A] 
is the molar concentration of agonist and EC50 is the molar concentration of agonist required to give a response 
which is halfway between the bottom and top responses. Data are presented as percentage of DAMGO after 
normalisation to the bottom and top values of the DAMGO response. Fitting concentration-response curves with 
a variable Hill slope shared between agonists produced slopes not significantly different to one for most assays, 
and nested extra sum-of-squares F-tests preferred the simpler fixed-slope model. 
 
For the determination of τ values and transduction coefficients (log(τ/KA)), concentration–response data were fit 
to the operational model (70) - partial agonism equation: 
 
Y = Basal +  
Em − Basal
1 +  (
10𝑙𝑜𝑔𝐾𝐴 +  10𝑙𝑜𝑔[𝐴]
10𝑙𝑜𝑔τ 10𝑙𝑜𝑔[𝐴]
)
𝑛 
 
where Em is the maximal possible response of the system, Basal is the basal level of response, KA represents the 
equilibrium dissociation constant of the agonist (A) and τ is an index of the signaling efficacy of the agonist, 
and n is the slope of the transducer function. The analysis assumes that the transduction machinery utilized for a 
given cellular pathway are the same for all agonists, such that the basal, Em and n are shared between agonists. 
Within each individual experiment, basal activity was constrained to 0 and Em was constrained to 100. The 
value of n was constrained to 1 as protein-protein interaction assays of Nb33, mGsi, GRK and β-arrestin 2 
recruitment, as well as Rab5 trafficking, are linear under operational model assumptions . As noted above, test 
fitting of concentration-response curves to a variable Hill slope, that is n ≠ 1, did not provide evidence for 
operational analysis with a variable value of ‘n’ in the remaining assays. Within each individual experiment, τ 
and log(τ/KA) values were calculated using DAMGO as the reference agonist. In the instances where low 
efficacy agonists become full agonists (i.e. in G protein activation and AC inhibition assays), logKA was 
assumed to be equal to the logKA value of each agonist obtained in the mGsi recruitment assay. Functional 
affinity of each agonist for the receptor state producing a mGsi interaction likely reflects affinity for the active, 
G protein coupling receptor state. In the case of the GIRK membrane-potential assay, log(τ/KA) and τ estimates 
were generated by simultaneous curve fitting of the untreated and ß-CNA treated concentration-response curves. 
 
Biased agonism was quantified as previously described (22, 71). To exclude the impact of cell-dependent and 
assay-dependent effects on the observed agonism at each pathway, the log(τ/KA) value of a reference agonist, in 
this case DAMGO, was subtracted from the log(τ/KA) value of the agonists of interest to give a ΔLog(τ/KA) 
value with error propagated according to standard rules. The bias was then calculated for each agonist at two 
different signalling pathways by subtracting the Δlog(τ/KA) of one pathway from the second pathway to give a 
ΔΔlog(τ/KA) value, with error again propagated. Degrees of freedom of the resulting variable, for calculation of 
95% confidence intervals as shown in figures, and for statistical testing, was estimated by the Welch-
Satterthwaite equation due to unequal variance of the fitted parameters between assays. A lack of biased 
agonism will result in values of ΔΔlog(τ/KA) not significantly different from 0. When fold changes in bias are 
described, this was calculated by converting values of ΔΔlog(τ/KA) to the corresponding antilog value.  
 
Biased agonsim was statistically tested by a one sample t-test comparing a given ΔΔlog(τ/KA) value to 0, the 
subtracted value of the reference agonist DAMGO. P-values of this test were multiplicity corrected using the 
Holm-Sidak method within each set of comparisons. One sample statistical tests to 0 performed for Fig. 5 (all 
agonists compared between -arrestin 2 recruitment with GRK2 overexpression and Nb33/mGsi/GPA/ 
cAMP/GIRK assays for a total of 38 compairsons) and performed for fig. S6B (all agonists compared between 
-arrestin 2 recruitment with endogenous GRK and Nb33/mGsi/GPA/cAMP/GIRK assays for an additional, 
separate 38 compairsons) were multiplicity corrected within those sets of analyses. 
 
 
Correlations were computed using Pearson’s correlation analysis to assess whether the τ values of each agonist 
in a particular pathway vary together with the τ values of the same agonist in a different pathway. A strong 
correlation was reported when P < 0.05 and the fraction of the variance that is “shared” between the two 
variables is reported as R2. 
 
Membrane potential assay 
MOR mediated activation of potassium channels was assayed using a membrane-potential dye from Molecular 
Devices (FLIPR Membrane Potential Assay kit) as previously described (72). On the day before the experiment, 
HEK293-GIRK4-MOR cells were plated into clear bottomed, black walled 96 well plates (Corning) pre-coated 
with poly-D-lysine for cell adherence. Cells were plated in L-15 media (Gibco ThermoFisher) supplemented 
with 1% v/v FBS. The following day, cell medium was aspirated and plates were treated with either 200 nM -
chlornaltrexamine hydrochloride (SigmaAldrich) or HEPES-buffered salt solution (HBSS) vehicle control for 
20 minutes. Testing of each compound in untreated and -CNA treated conditions was carried out in parallel. 
All experiments were carried out in duplicate. Cells were washed twice with HBSS following vehicle or ß-CNA 
treatment and incubated for 1 hour in 50% L-15 media, 50% FLIPR dye reconstituted in HBSS in a final 
volume of 180 µL per well. All test compounds were serially diluted in a vehicle of 1% v/v DMSO, 0.1  mg/mL 
bovine serum albumin (BSA in HBSS at 10x concentrations in a 96 well compound plate (Corning) such that 
final assay concentrations of solvent were 0.1% DMSO and 0.01 mg/mL BSA. Plates were read in a FlexStation 
3 (Molecular Devices). Two-minute baselines were taken for each well before compound addition. Then 20 µL 
of 10x concentrated compound were added, and read for three minutes. Peak effect was calculated by taking the 
minimum raw fluorescence value of the post-addition measurement period, expressed as a percentage of pre-
addition baseline and vehicle corrected, and normalised to the maximal response to DAMGO without -CNA 
treatment. 
 
Animals 
All experiments involving animals were approved by the University of Sydney Animal Ethics Committee (AEC. 
Protocol number K00/12-2011/3/5650). Experiments were performed under the guidelines of the Australian 
code of practice for the care and use of animals for scientific purposes (National Health and Medical Research 
Council, Australia, 7th Edition). Great care was taken to minimize animal suffering during these experiments 
and to reduce the number of animals used. Male C57Bl/6J mice were ordered from the Animal Resource Centre 
(Perth, Western Australia) and were between 6 and 9 weeks of age on the day of experimentation. Animals were 
housed no more than 6 to an individually ventilated cage in a temperature and humidity-controlled room with 
12-hour reverse day-night cycle lighting (lights on at 20:00). Mice had free access to food and water and were 
allowed to acclimatise to the facility for at least 10 days before the experimental day. All animal experiments 
were performed on mice between 9:00 and 19:00 hours in their dark, active period under a red light. Handling 
and acclimatisation of animals to the testing room occurred on at least four days before experimentation.  
 
Doses in milligram per kilogram were calculated for the active component of the drug (free base). Morphine 
hydrochloride, fentanyl citrate, PZM21 hydrochloride and oliceridine hydrochloride were dissolved in saline for 
injection. Buprenorphine hydrochloride was dissolved in 20% polyethylene glycol 400 in saline. SR-17018 
hydrochloride was dissolved in 1% v/v DMSO, 10% v/v Tween 80 and hydrochloric acid, before being diluted 
to a final concentration in saline and pH adjusted back to 7 with sodium hydroxide. Saline, 20% PEG and 1% 
DMSO/10% Tween 80 vehicles did not differentially affect either the hot-plate or whole body plethysmography 
assays. All injections were performed sub-cutaneously (s.c.) at a volume of 200 µL, with the exception of SR-
17018 and the 1% DMSO/10% Tween 80 vehicle which were administered intra-peritoneal (i.p.) at a volume of 
400 µL.  
 
Hot-plate assay 
Anti-nociception was tested using a 54 ºC hot-plate with latency to response timed via foot-switch. Mice were 
placed onto the hot-plate within a plexiglass cylinder and observed at baseline and post-injection time-points of 
5, 15, 30, 60, 90, 120 and 180 minutes. Hot-plate response was defined by hindpaw lift, flick, flutter or 
attending, or, rarely, a jump. Mice were rapidly removed from hot-plate following response or at cut-off. A 
maximum cut-off of 20 s was set to limit potential tissue damage. Experimenters were blind to drug or vehicle 
treatment group via coded syringe labelling. Responses have been expressed as percentage of maximum 
possible effect, by subtracting each animal’s baseline latency and normalising to the cut-off latency. 
 
Whole-body plethysmography 
Respiratory side effects were tested using a commercial whole-body plethysmography (WBP) system (Buxco 
FinePointe system, DSI Instruments). Animals were acclimatised to one of two parallel WBP chambers on the 
day before the experiment for 10 - 15 minutes, and again on the morning of the experiment. While in WBP 
chambers, animals were shielded from view from other animals and the experimenter. Chamber air was 
refreshed from room air by the integrated system at a constant rate. All analysis of respiratory waveforms was 
completed by integrated FinePointe software. With the exception of fentanyl citrate, the respiratory effects of 
test compounds were examined in a rotating protocol in which 10 minute measurements were taken at a pre-
injection baseline followed by 25, 65, 105 and 230 minutes post-injection. Animals settled in the WBP 
chambers over the first 5-minute period, and the second 5-minute period was taken for analysis. Four animals 
were rotated through a single chamber in this manner over the testing period. Due to the extremely rapid 
kinetics of fentanyl citrate, an alternative rapid rotating protocol was used. Mice were returned to the chamber 
immediately following injection for an initial 15 minute measurement, after which 10 minute measurements 
were taken at 35, 65, 95, 125 and 215 minutes post-injection, with two animals rotated through each chamber. 
For analysis, each animal’s respiratory frequency was normalised to the pre-drug baseline as 100%. 
 
In vivo dose-response analysis 
The peak response of each animal was taken for each compound for dose-response curve fitting. For comparison 
between hot-plate and WBP assays, only time-points captured in both assays were included in analysis. Plots 
were fitted to a three-parameter logistic function, with basal constrained to 0. In fitting the hot-plate assay, curve 
maximum was constrained to be less than the maximum possible effect. In WBP, ED50 values were calculated at 
50% of the maximum response to fentanyl. Therapeutic window was calculated between the two assays by 
subtraction of log(ED50) values to produce Δlog(ED50). Error was propagated by standard rules, and degrees of 
freedom for statistical testing summed under the assumption of consistent variance. In the case of compounds 
that did not reach 50% of defined maximum response in the WBP assay, SR-17018 and buprenorphine, the 
therapeutic window was calculated by assuming that the ED50 must be greater than the highest dose tested. The 
95% C.I. of the Δlog(ED50) calculated for these compounds is therefore asymmetrical, with uncertainty in one 
direction unbounded. The maximum dose of PZM21, SR-17018 and buprenorphine in WBP were compared to 
the corresponding vehicle at each time point using multiple t-tests, with multiple comparisons adjusted for using 
the Holm-Sidak method. 
 
Conversion of free base buprenorphine, SR17018, PZM21 to their monohydrochloride salt  
All solvents and reagents were purchased and used from commercial sources. Nuclear magnetic resonance 
spectra were recorded on Bruker Advance DRX 300 at 300 MHz 1H NMR frequency, chemical shifts are 
expressed as parts per million (ppm). All resonances are reported as chemical shift (δ) and are referenced to the 
solvent residual peak. Multiplicities are reported as follows: s (singlet), br (broad), d (doublet), dd (doublet of 
doublets), t (triplet), q (quartet) and m (multiplet). Coupling constants (J) are reported in Hz. 
Low- and high-resolution mass spectra were obtained through electron ionisation (ESI). Low- resolution mass 
spectra were performed on a Finnigan LCQ mass spectrometer. High-resolution mass spectra were performed 
on a Bruker 7T Apex Qe Fourier Transform Ion Cyclotron resonance mass spectrometer equipped with an 
Apollo II ESI/APCI/MALDI Dual source. 
High performance liquid chromatography (HPLC) was performed on the Waters Alliance 2695 apparatus 
equipped with Waters 2996 photodiode array detector, set at 254 nm. Separation using a SunFireTM C18 
column (5 μm, 2.1 x 150 mm) was achieved using water (solvent A) and acetonitrile (solvent B) at a flow rate of 
0.2 mL/min. The method consisted of 0% B to 100% B over 30 minutes. HPLC data is recorded as  percentage 
purity and retention time (RT) in minutes. All compounds showed >95% analytical purity.  
 
 
 
A solution of free base drug (1.00 mmol) in diethyl ether (10 mL, 0.1 mM concentration) was treated with a 4 M 
solution of HCl in 1,4-dioxane (1.0 mL, 4.0 mmol) and stirred for 1 hour with a white precipitate formed. The 
solvent was removed under reduced pressure and the solid obtained dried to constant mass under high vacuum.  
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Buprenorphine hydrochloirde SR-17018 hydrochloride PZM21 hydrochloride
 Buprenorphine hydrochloride 
White solid. 1H NMR (300 MHz, DMSO-d6) δ 6.65 (d, J = 8.0 Hz, 1H), 6.40 (d, J = 8.0 Hz, 1H), 5.85 (s, 1H), 
5.36 (br. s, 1H), 4.42 (d, J = 0.9 Hz, 1H), 3.51 (s, 3H), 3.05 – 2.89 (m, 3H), 2.59 (dd, J = 10.9, 4.8 Hz, 1H), 2.42 
– 2.20 (m, 4H), 2.17 (m, 1H), 1.96 (m, 1H), 1.85 – 1.67 (m, 3H), 1.35 (s, 3H), 1.32 (m, 1H), 1.06 (m, 1H), 1.04 
(s, 9H), 0.81 – 0.69 (m, 2H), 0.54 – 0.43 (m, 2H), 0.10 (m, 2H), NH signal not observed; LRMS (+ESI) m/z: 
468 (100, [M + H]+); HRMS (+ESI) m/z: [M + H]+ calcd for C29H42NO4: 468.3108; found 468.3106. 
 
SR-17018 hydrochloride 
White solid. 1H NMR (300 MHz, DMSO-d6) δ 11.25 (s, 1H), 7.55 (s, 1H), 7.40 – 7.20 (m, 4H), 7.15 (s, 1H), 
6.21 (p, J = 3.9 Hz, 1H), 4.27 (br. s, 1 H), 3.72 (s, 2H), 3.01 (m, 2H), 2.55 (m, 2H), 2.26 (m, 2H) 1.69 (m, 2H); 
LRMS (+ESI) m/z: 410/412 (100/98, [M + H]+); HRMS (+ESI) m/z: [M + H]+ calcd for C19H1935Cl3N3O: 
410.0588; found 410.0590. 
 
PZM21 hydrochloride 
White solid. 1H NMR (300 MHz, DMSO-d6) δ 9.13 (s, 1H), 7.40 (dd, J = 4.9, 2.9 Hz, 1H), 7.09 (dd, J = 3.0, 1.2 
Hz, 1H), 7.02 – 6.98 (m, 3H), 6.70 – 6.60 (m, 2H), 6.00 (d, J = 7.9 Hz, 1H), 5.55 (dd, J = 7.5, 2.6 Hz, 1H), 4.55 
(br. s, 1 H), 3.79 (m, 1H), 3.04 (m, 1H), 2.85 – 2.60 (m, 3H), 2.62 – 2.50 (m, 2H), 2.34 (s, 6H), 2.17 (dd, J = 
13.4, 9.3 Hz, 1H), 0.94 (d, J = 6.6 Hz, 3H).; LRMS (+ESI) m/z: 362 (100, [M + H]+); HRMS (+ESI) m/z: [M + 
H]+ calcd for C19H28N3O2S: 362.1897; found 362.1897. 
 
Förster resonance energy transfer (FRET) measurements 
To measure the interaction between MOR and ß-arrestin 2, HEK293T cells were transfected with 0.8 µg of 
MOR-YFP, 0.4 µg of human GRK2, and 0.8 µg of ß-arrestin 2–mTurquoise. On the next day, cells were seeded 
on round 25-mm poly-d-lysine–coated coverslips, and 48 hours after transfection, FRET was measured as 
previously described (36) (73), except that a light- emitting diode (LED) excitation system (pE-2; CoolLED) 
was used for all experiments. FRET traces were not corrected for bleaching effects. 
  
Supplementary Materials  
Fig. S1. Additional concentration-response curves.Concentration response curve for opioid ligands in GIRK 
activation in the absence of --chlornaltrexamine treatment, and for -arrestin 2 recruitment and Rab5 
trafficking in the absence of GRK2 overexpression.  
Fig. S2. Kinetics of Nb33 and mGsi recruitment and naloxone antagonism. Kinetics of Nb33 and mGsi 
recruitment to MOR for DAMGO, oliceridine, PZM21, SR-17018 and buprenorphine 
Fig. S3. Sensitivity of MOR phosphorylation to naloxone and Cmpd101. 
Fig. S4. Kinetics of interaction of MOR with ß-arrestin 2 by FRET.Arrestin recruitment induced by DAMGO, 
morphine, SR-17018, PZM21 and oliceridine measured using a FRET approach 
Fig. S5. Correlation matrix and statistical testing of correlation between log(τ) values .Pearson r and SEM of 
log() correlations 
Fig. S6. Additional bias calculations.Log(/KA) for the different agonists across the different signalling 
pathways, biased factors Log(/KA) in the absence of GRK2 overexpression and log() calculation of 
efficacy-driven bias. 
Fig. S7. Opioid-induced respiratory depression shown analyzed as minute volume. 
Fig. S8. Therapeutic window compared to efficacy and G-protein or ß-arrestin 2 bias for additional signaling 
assays.Relationships of the therapeutic windows of these ligands with the operational efficacies or bias factors at 
other signalling endpoints. 
Fig. S9. Bias plots for all additional assays.Bias plots of -arrestin 2 recruitment and Nb33, mGsi, cAMP 
inhibition and GIRK channel activation. 
Table S1. Calculation of transduction coefficients. 
Table S2. G protein efficacy estimated from previous publications. 
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Figure Legends 
 
Fig. 1. Oliceridine, PZM21, and SR-17018 have low intrinsic efficacy for receptor activation and G 
protein signaling. (A) Schematic showing the signalling pathways induced by MOR agonists (star) 
investigated.  Recruitment of Gi leads to inhibition of AC and therefore a reduction in cAMP. (B to F) 
Concentration-response curves for DAMGO, fentanyl, methadone, morphine, oxycodone, oliceridine, PZM21, 
SR-17018, and buprenorphine were determined for recruitment of the conformationally selective nanobody 
Nb33 (B), recruitment of mini Gi-protein (mGsi) (C), activation of Gi2 (D), inhibition of Fsk-induced cAMP 
accumulation (E), and GIRK channel activation upon inactivation of MOR with -CNACNA (see fig. S1 for 
GIRK channel activation in the absence of -CAN) (F). All responses were normalized to the response induced 
by 10 µM DAMGO. Data are means ± SEM of three to ten experiments, each performed in duplicate (F) or 
triplicate (B–E).  
 
Fig. 2. Low intrinsic–efficacy opioid ligands show limited recruitment of regulatory proteins and 
internalization. (A) Schematic showing the regulatory pathways investigated. Upon receptor activation, MOR 
is phosphorylated by GRK2, prompting the recruitment of -arrestin 2 to the receptor and initiating receptor 
internalization towards early endosomes XXXX. (B to D) Concentration-response curves for DAMGO, 
fentanyl, methadone, morphine, oxycodone, oliceridine, PZM21, SR-17018, and buprenorphine were 
constructed for GRK2 recruitment (B), -arrestin 2 recruitment (C), and MOR trafficking to Rab5-positive 
endosomes (D). All responses were normalised to the response induced by 10 µM DAMGO. Data are means ± 
SEM of three to fourteen experiments, each performed in triplicate. (E) The operational efficacy log() for the 
partial agonists was calculated and plotted as a heatmap.   
 
Fig. 3. Receptor phosphorylation barcode correlates with efficacy profiles.  (A) HEK293 cells stably 
expressing HA-tagged MOR were stimulated with increasing concentrations of fentanyl, methadone, morphine, 
oxycodone, oliceridine, PZM21, or SR-17018 for 30 min. Cells were lysed and immunoblotted for MOR 
phosphorylated at Thr370 (pT370), Ser375 (pS375), Thr376 (pT376), and Thr379 (pT379). Blots were stripped and 
reprobed with an antibody against HA to confirm equal loading of HA-MOR. (B) HEK293 cells stably 
expressing HA-MOR were stimulated with 10 µM DAMGO or 10 µM SR-17018 and phosphorylation of Thr370, 
Ser375, Thr376, and Thr379 was assessed at different time points. Blots are representative of three independent 
experiments. 
 
Fig. 4. Correlations between efficacies of opioid ligands across multiple signaling pathways. (A to D) 
Correlation of the operational efficacy, log(), for Gi2 activation by the partial agonists morphine, oxycodone, 
oliceridine, PZM21, SR-17018, and buprenorphine, as calculated from the concentration-response curves (Figs. 
1 and 2, Materials and Methods), with the log() obtained for receptor activation, as measured by Nb33 
recruitment (A) and for recruitment of mGsi (B), cAMP inhibition (C), and G-mediated GIRK activation (D). 
(E to G) Correlation of the operational efficacy, log(),  calculated for -arrestin 2 recruitment with the log() 
obtained for Nb33 recruitment (E), GRK2 recruitment (F), and MOR trafficking to Rab5-positive endosomes 
(G). (H to K) Correlation of the log() for -arrestin 2 recruitment with that of G protein–mediated signaling 
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pathways, including mGsi recruitment (H), Gi2 (I) and GIRK channel (J) activation, and, to a lesser degree, 
with inhibition of Fsk-induced cAMP accumulation (K). 
 
Fig. 5. Bias factor calculations for opioid ligands. Bias factors of all opioids were calculated using DAMGO 
as a reference (see Materials and Methods). *, ** p<0.05, p<0.01 by one sample t-test. Error was propagated 
using standard rules, and error bars represent 95% confidence intervals.  
 
Fig. 6. Opioid-induced antinociception and respiratory depression. (A) Antinociception was measured for 
180 min using the hot plate assay and increasing doses as noted (in mg/kg XX) of fentanyl, morphine, 
oliceridine, PZM21, SR-17018, or buprenorphine. Data are normalized to the maximal possible effect (%MPE) 
and are mean ± SEM of three to nine animals (n shown in parentheses for each dosage). (B) Respiratory 
depression was measured for 240 min using whole-body plethysmography in freely moving animals and 
increasing doses of fentanyl, morphine, oliceridine, PZM21, SR-17018, or buprenorphine. Data are normalized 
to baseline respiratory rate and are mean ± SEM of five to nine animals (n shown in parentheses). (C) The 
response of equi-effective doses in antinociception was compared to the respiratory depression assay. *, **, ***, 
p<0.05, 0.01, 0.001 by multiplicity-corrected t-test compared to vehicle for peak dose of PZM21, SR-17018, 
and buprenorphine. All drugs were administered subcutaneously except for SR-17018, which was administered 
intraperitoneally. 
 
Fig. 7. Therapeutic windows of opioid ligands. (A) Dose-response analysis of fentanyl, morphine, oliceridine, 
PZM21, SR-17018, and buprenorphine in antinociception and respiratory depression assays. Peak effect (Figs. 
6A and 6B) is plotted for each dose, with hot-plate (HP) plotted on the left Y axis and whole-body 
plethysmography (WBP) on the right Y axis. (B) Potency [log(ED50)] of each agonist for anti-nociception and 
respiratory depression. Because curve fit was not possible for SR-17018, potency for antinociception was taken 
as minimum dose reaching 50% MPE. In the case of respiratory depression induced by buprenorphine and SR -
17018, neither of which reached 50% the maximum effect of fentanyl, the highest tested dose is represented as a 
minimum lower bound of potency. 
 
Fig. 8. The therapeutic window of opioid ligands is inversely correlated with their intrinsic efficacy. The 
therapeutic windows for fentanyl, morphine, oliceridine, PZM21, SR-17018, and buprenorphine were calculated 
by subtraction of logED50 of antinociception from respiratory depression,  log(ED50) (Fig. 7) and the error 
propagated. Therapeutic windows were then plotted against (A) the operational efficacy log() obtained for mini 
Gi recruitment or (B)the bias factors, Log(/KA). The therapeutic windows of SR-17018 and buprenorphine 
were estimated and are shown as lower bounds. The relationships of the therapeutic windows of these ligands 
with the operational efficacies or bias factors at other signaling endpoints is shown in fig. S8. The operational 
efficacy of fentanyl for mGsi recruitment shown here is an estimated value. 
 
Fig. 9. Overexpression of GRK2 does not alter bias. Data from Fig. 1 and Fig. 2 was used to plot the 
equimolar comparison of the different opioid agonists activities in G protein activation and -arrestin 2 
recruitment in the presence or absence of GRK2.  
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 Table 1. Determination of the maximal responses (Emax) of selected agonists for all the pathways 
measured at the MOR. Values are expressed as mean ± SEM from three to fourteen independent experiments. 
Emax 
% of DAMGO 
Nb33 mGsi GPA cAMP 
GIRK 
(untreated) 
GIRK 
(ß-CNA) 
DAMGO 100 100 100 100 100 75 ± 5 
Fentanyl 102 ± 6 104 ± 6 103 ± 2 100 ± 5 95 ± 4 74 ± 7 
Methadone 88 ± 5 107 ± 3 105 ± 2 106 ± 3 ND ND 
Morphine 71 ± 3 80 ± 7 98 ± 5 97 ± 4 88 ± 4 56 ± 3 
Oxycodone 70 ± 4 75 ± 3 103 ± 4 106 ± 7 ND ND 
Oliceridine 42 ± 8 51 ± 7 85 ± 5 86 ± 5 74 ± 4 38 ± 3 
PZM21 38 ± 3 52 ± 5 86 ± 7 84 ± 7 86 ± 3 40 ± 2 
SR-17018 20 ± 6 35 ± 5 61 ± 13 62 ± 12 78 ± 7 33 ± 6 
Buprenorphine 26 ± 3 36 ± 3 79 ± 6 86 ± 9 54 ± 5 19 ± 3 
 
Emax 
% of DAMGO 
GRK2 βArr2 Rab5 
βArr2  
(GRK2) 
Rab5  
(GRK2) 
 
DAMGO 100 100 100 100 100  
Fentanyl 105 ± 5 70 ± 4 79 ± 13 92 ± 2 88 ± 4  
Methadone 107 ± 9 88 ± 3 77 ± 3 100 ± 3 98 ± 6  
Morphine 66 ± 6 28 ± 3 51 ± 10 70 ± 3 75 ± 5  
Oxycodone 64 ± 8 23 ± 4 - 72 ± 5 64 ± 3  
Oliceridine 40 ± 3 16 ± 3 - 58 ± 3 49 ± 4  
PZM21 36 ± 7 14 ± 3 - 59 ± 4 51 ± 3  
SR-17018 41 ± 9 12 ± 1 - 49 ± 7 59 ± 9  
Buprenorphine 28 ± 5 - - 34 ± 2 25 ± 9  
 
  
Table 2. Determination of the potencies (pEC50) of selected agonists for all the pathways measured at the 
MOR. Values are expressed as mean ± SEM from three to fourteen independent experiments. 
 
pEC50 Nb33 mGsi GPA cAMP 
GIRK 
(untreated) 
GIRK 
(ß-CNA) 
DAMGO 6.76 ± 0.04 7.03 ± 0.17 7.94 ± 0.16 8.48 ± 0.29 8.69 ± 0.05 7.29 ± 0.17 
Fentanyl 7.36 ± 0.09 7.64 ± 0.10 8.68 ± 0.16 9.20 ± 0.23 9.30 ± 0.09 8.34 ± 0.23 
Methadone 6.67 ± 0.05 6.99 ± 0.06 8.00 ± 0.18 8.22 ± 0.17 ND ND 
Morphine 6.67 ± 0.03 6.94 ± 0.05 7.72 ± 0.16 8.10 ± 0.26 7.98 ± 0.10 7.16 ± 0.17 
Oxycodone 5.93 ± 0.12 6.22 ± 0.11 6.94 ± 0.23 7.01 ± 0.18 ND ND 
Oliceridine 7.19 ± 0.28 7.46 ± 0.18 8.38 ± 0.19 8.66 ± 0.13 8.43 ± 0.12 7.88 ± 0.33 
PZM21 6.88 ± 0.36 7.49 ± 0.14 8.16 ± 0.19 8.64 ± 0.25 8.42 ± 0.07 7.78 ± 0.22 
SR-17018 7.48 ± 0.46 7.15 ± 0.33 7.66 ± 0.18 7.67 ± 0.33 6.43 ± 0.13 6.18 ± 0.30 
Buprenorphine 8.28 ± 0.21 8.65 ± 0.14 8.85 ± 0.06 9.61 ± 0.37* 7.97 ± 0.21 7.93 ± 0.43 
 
pEC50 GRK2 βArr2 Rab5 
βArr2  
(GRK2) 
Rab5  
(GRK2) 
 
DAMGO 6.83 ± 0.08 6.27 ± 0.08 6.13 ± 0.15 7.55 ± 0.09 6.97 ± 0.12  
Fentanyl 7.33 ± 0.15 7.10 ± 0.06 6.73 ± 0.13 8.08 ± 0.07 7.74 ± 0.07  
Methadone 6.76 ± 0.07 6.39 ± 0.11 6.44 ± 0.23 7.15 ± 0.10 7.17 ± 0.27  
Morphine 6.78 ± 0.08 6.48 ± 0.27 6.25 ± 0.35 7.31 ± 0.13 6.87 ± 0.10  
Oxycodone 6.28 ± 0.09 6.77 ± 0.56 - 6.22 ± 0.06 6.25 ± 0.25  
Oliceridine 7.26 ± 0.51 6.45 ± 0.26 - 7.71 ± 0.08 7.21 ± 0.26  
PZM21 7.58 ± 0.19 7.36 ± 0.84 - 7.56 ± 0.07 7.56 ± 0.23  
SR-17018 6.99 ± 0.19 8.40 ± 0.47 - 6.48 ± 0.46 7.06 ± 0.39  
Buprenorphine 7.95 ± 0.28 - - 8.50 ± 0.21 6.98 ± 6.78  
 
  
Table 3. Determination of the efficacies (τ) of selected agonists for all the pathways measured at the 
MOR. Values are expressed as mean ± SEM from three to fourteen independent experiments. Efficacy of 
olicerdine, PZM21, SR-17018, and buprenorphine were compared to morphine in a two-way ANOVA with a 
Holm-Sidak multiple comparisons corrected post-hoc test. * p<0.05, ** p<0.01, *** p<0.001. 
 
Log τ Nb33 mGsi GPA cAMP GIRK 
Morphine 0.42 ± 0.08 0.70 ± 0.07 1.74 ± 0.22 2.00 ± 0.31 0.09 ± 0.05 
Oxycodone 0.56 ± 0.12 0.65 ± 0.09 1.86 ± 0.26 1.87 ± 0.22 ND 
Oliceridine -0.34 ± 0.12*** -0.12 ± 0.05** 1.15 ± 0.25 1.29 ± 0.23** -0.24 ± 0.05 
PZM21 -0.33 ± 0.07*** -0.08 ± 0.08** 1.18 ± 0.28 1.44 ± 0.39* -0.18 ± 0.04 
SR-17018 -0.86 ± 0.21*** -0.37 ± 0.16*** 0.66 ± 0.37*** 1.04 ± 0.28** -0.28 ± 0.12 
Buprenorphine -0.62 ± 0.09*** -0.40 ± 0.05*** 0.63 ± 0.25*** 1.35 ± 0.39* -0.61 ± 0.10** 
 
Log τ GRK2 
βArr2  
(GRK2) 
Rab5  
(GRK2) 
Morphine 0.21 ± 0.07 0.34 ± 0.07 0.45 ± 0.18 
Oxycodone 0.22 ± 0.14 0.35 ± 0.09 0.11 ± 0.16 
Oliceridine -0.30 ± 0.18 0.13 ± 0.03 -0.08 ± 0.13* 
PZM21 -0.37 ± 0.11 0.11 ± 0.06 -0.06 ± 0.18 
SR-17018 -0.30 ± 0.09 -0.04 ± 0.15 0.04 ± 0.15 
Buprenorphine -0.57 ± 0.08 -0.30 ± 0.09* -0.84 ± 0.32*** 
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